Pharmaceutical Value (pValue) - headquartered within the University of Colorado's Anschutz Medical Campus - aims to apply and test novel methods for value assessment that encourages stakeholder engagement and promotes value-based decision making. pValue is a recipient of the PhRMA Foundation's Value Assessment Initiative Centers of Excellence Award.
Pharmaceutical Value (pValue)’s mission is to apply and test novel methods to improve pharmaceutical coverage and reimbursement decision-making.
Traditional measures of value used in cost-effectiveness analyses are not, by definition, fully comprehensive or sufficiently flexible to allow for the inclusion of all the criteria that patients, payers, clinicians, or other health care stakeholders care about. Multi-criteria decision analysis (MCDA) offers a scientifically rigorous decision-making tool capable of including multiple criteria that are important to stakeholders. MCDA has been applied in a variety of sectors, such as investment banking and environmental management, but applications in US healthcare decision making have been limited.
MCDA can improve decision making in health care by engaging key stakeholders and by capturing and weighing criteria not found in traditional measures of value, for example novelty, severity of disease, quality of evidence, and family burden. By encouraging a comprehensive understanding of value, MCDA offers an opportunity to systematically weigh non-traditional aspects of value that fall outside traditional measures of value.
Complementing Coverage and Reimbursement Decisions With Multi-Criteria Decision Analysis
Featuring Dr. Brett McQueen and Dr. Jon Campbell
Industry Voices—Using PCORI to advance patient-centered values
Featuring Dr. Brett McQueen
CU Anschutz investigators receive PhRMA Foundation Award
Featuring Dr. Brett McQueen and Dr. Jon Campbell